GF Fund Management’s Enanta Pharmaceuticals ENTA Stock Holding History

GF Fund Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$8.82K	Buy	669 +52	+8%	+$690	﹤0.01%	550
2026 Q2	$9K	Sell	617 -23	-4%	-$309	﹤0.01%	545
2026 Q1	$8.08K	Buy	640 +75	+13%	+$1K	﹤0.01%	579
2025 Q4	$8.91K	Buy	565 +117	+26%	+$1.49K	﹤0.01%	584
2025 Q3	$5.36K	Sell	448 -77	-15%	-$615	﹤0.01%	607
2025 Q2	$3.97K	Hold	525	–	–	﹤0.01%	637
2025 Q1	$2.9K	Buy	525 +80	+18%	+$494	﹤0.01%	642
2024 Q4	$2.56K	Buy	+445	New	+$4.27K	﹤0.01%	632

Other funds holding ENTA

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

Pinnacle Wealth Planning Services Mansfield, Ohio $1.03B AUM 22.32% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

GF Fund Management's ENTA Position: Q3 2026 in Review

GF Fund Management increased its Enanta Pharmaceuticals (ENTA) stake by 8.4% in Q3 2026, buying an estimated $690 and bringing the position to 669 shares worth $8.82K. The position accounts for ﹤0.01% of the portfolio, ranked #550.

GF Fund Management first reported a position in ENTA in Q4 2024 and has held it in 8 quarters since. The position peaked at $9K in Q2 2026. 16 funds tracked by Wall St. Rank hold ENTA as of Q3 2026.

GF Fund Management held 669 shares of Enanta Pharmaceuticals worth $8.82K as of Q3 2026.
GF Fund Management bought 52 Enanta Pharmaceuticals shares in Q3 2026, an estimated $690.
Enanta Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q3 2026, its #550 holding.
GF Fund Management first reported a position in Enanta Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
GF Fund Management's Enanta Pharmaceuticals position peaked at $9K in Q2 2026.
16 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2026.

Based on GF Fund Management's 13F filing for Q3 2026, filed 26 Oct 2026.